Phosphorylethanolamine

Phosphorylethanolamine

SCHEMBL3824970

CCCCCC(O)(CCCCC)[C@@H](O)CO.NCCOP(=O)(O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 4/20 0.45
LPAR1 Q92633 2/20 0.45
LPAR2 Q9HBW0 2/20 0.45
SMPD1 P17405 5/20 0.41
FDPS P14324 7/20 0.41
LPAR5 Q9H1C0 1/20 0.40
GGPS1 O95749 3/20 0.38
PLA2G2D Q9UNK4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10594311 0.81 PLA2G2C (0.50) SMPD1FDPSGGPS1PLA2G2D
SCHEMBL8472151 0.80 PLA2G2C (0.41) LPAR3LPAR1LPAR2SMPD1FDPS
Phosphorylethanolamine SCHEMBL993264 0.80 LPAR3 (0.44) LPAR3LPAR1LPAR2LPAR5
SCHEMBL9115436 0.79 PLA2G2C (0.43) LPAR3LPAR1LPAR2SMPD1FDPS
SCHEMBL10594234 0.78 LPAR5 (0.50) LPAR3LPAR1LPAR2SMPD1FDPS
SCHEMBL2596151 0.78 LPAR5 (0.50) LPAR3LPAR1LPAR2SMPD1FDPS
Phosphorylethanolamine SCHEMBL19412013 0.78 LPAR3 (0.42) LPAR3LPAR1LPAR2LPAR5
SCHEMBL302211 0.77 FDPS (0.39) FDPSGGPS1
SCHEMBL2039696 0.77 FDPS (0.39) FDPSGGPS1
Phosphorylethanolamine SCHEMBL28264156 0.76 LPAR3 (0.64) LPAR3LPAR1LPAR2LPAR5PLA2G2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086508-A2 CATIONIC COLLOIDAL CARRIERS FOR DELIVERY OF ACTIVE AGENTS TO THE BLOOD-BRAIN BARRIER IN THE COURSE OF NEUROINFLAMMATORY DISEASES MediGene Aktiengesellschaft (DE) 2009-08-12 EP disclosed
WO-2008052766-A2 CATIONIC COLLOIDAL CARRIERS FOR DELIVERY OF ACTIVE AGENTS TO THE BLOOD-BRAIN BARRIER IN THE COURSE OF NEUROINFLAMMATORY DISEASES MEDIGENE AG (DE) 2008-05-08 WO disclosed